Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2025
Schedule of Pharmaceutical Benefits - 1 February 2025
1 February 2025 - The February 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Feb 2025
New Zealand Pharmaceutical Schedule - 1 February 2025
1 February 2025 - The February 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Feb 2025
Boehringer Ingelheim’s Jardiance gets expanded coverage for HFpEF patients
31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded ...
Posted by Michael Wonder on 31 Jan 2025
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease in England
31 January 2025 - Agreement means eligible sickle cell disease patients in England now have access to Casgevy. ...
Posted by Michael Wonder on 29 Jan 2025
Von Hippel-Lindau disease drug Welireg listed on PBS slashing cost by $11,000 a month for patients
28 January 2025 - The treatment for Simon Goodrich’s disease has been costing $12,000 a month, but there has been a ...
Posted by Michael Wonder on 20 Jan 2025
Handok's AML treatment Vyxeos receives insurance coverage in Korea
2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin ...
Posted by Michael Wonder on 19 Jan 2025
Protection against RSV for mums and bubs with free vaccine available from 3 February
19 January 2025 - From 3 February 2025, Australian mums and their newborn babies will have free access to the best ...
Posted by Michael Wonder on 06 Jan 2025
Price must be right to put obesity pill on the PBS
6 January 2025 - Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for ...
Posted by Michael Wonder on 06 Jan 2025
Global pharma giants push for weight loss drugs to be added to PBS
6 January 2025 - Taxpayers would fund popular weight loss drugs for people with severe obesity under a proposal from ...
Posted by Michael Wonder on 27 Dec 2024
Alnylam Canada signs letter of intent from pan-Canadian Pharmaceutical Alliance for the public reimbursement of Amvuttra for the treatment of hereditary transthyretin-mediated amyloidosis in adults
18 October 2024 - One step closer to achieving public reimbursement of Amvuttra for hereditary transthyretin-mediated amyloidosis. patients in Canada ...
Posted by Michael Wonder on 14 Dec 2024
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for Pluvicto
13 December 2024 - Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA positive metastatic castration ...
Posted by Michael Wonder on 14 Dec 2024
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Tecentriq SC (atezolizumab solution for subcutaneous injection)
13 December 2024 - Roche Canada today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Tecentriq ...
Posted by Michael Wonder on 07 Dec 2024
Biden-Harris Administration takes next steps to increase access to sickle cell disease treatments
4 December 2024 - Today, the Biden-Harris Administration announced that two drug manufacturers with FDA approved gene therapies for sickle ...
Posted by Michael Wonder on 01 Dec 2024
Schedule of Pharmaceutical Benefits - 1 December 2024
1 December 2024 - The December 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 02 Nov 2024
Handok's rare blood disorder treatment Empaveli wins insurance coverage
1 November 2024 - Starting today, Handok's Empaveli (pegcetacoplan), a treatment for paroxysmal nocturnal haemoglobinuria, will be covered by Korean ...